| 2024-04-24 | +4.56 % |
|
| 2024-04-23 | -0.48 % |
|
| 2024-04-22 | -0.14 % |
- Summary: Federated Hermes Inc. decreased its stake in Biogen Inc. by 4.1% during the fourth quarter, while other institutional investors also either added or reduced their positions in the company, and Biogen stock was down by 0.14% on the day.
Reason for stock decline: Biogen stock may have dropped due to institutional investors, like Federated Hermes Inc., reducing their positions in the company, which could signal decreased confidence in the stock's performance. Additionally, insider transactions, such as shares being sold by Priya Singhal and purchased by Director Eric K. Rowinsky, may have contributed to market fluctuations and impacted the stock price.
- The article provides information about Biogen's (BIIB) upcoming earnings announcement, financial guidance, recent insider transactions, stock performance, and analyst ratings, indicating that its stock went down possibly due to missing earnings estimates in the previous quarter and lowered price target by research firms.
- The article provides insights into Knights of Columbus Asset Advisors LLC raising its position in Biogen Inc., and several other hedge funds purchasing shares, with institutional investors collectively owning 87.93% of the company's stock. Biogen's stock price went down, likely due to missing earnings estimates, restructuring activities, and insider selling.
|
| 2024-04-19 | +2.03 % |
- Biogen (BIIB) stock was up 2.03% last night as Pfizer and another drug manufacturer, among others, were making new lows on the stock market, with Biogen's decrease in price partially attributed to downgrades from analysts and a drop in price targets.
- The article reports that Biogen (BIIB) stock was up by 2.03% last night, and the increase can be attributed to optimistic price target adjustments and ratings issued by various equities research analysts, including Wedbush, Canaccord Genuity Group, and JPMorgan Chase & Co., along with positive earnings estimates for Q3 2024.
- The article discusses how Biogen (BIIB) stock was up by 2.03% and analyzes various analyst reports on the company, including price targets and ratings from different firms, while also mentioning recent insider trading activities within the company; the stock increase may be attributed to positive analyst ratings and insider purchases.
|
| 2024-04-17 | -1.53 % |
|
| 2024-04-15 | -0.7 % |
|
| 2024-04-12 | -2.7 % |
|
| 2024-04-11 | +1.06 % |
|
| 2024-04-10 | -2.41 % |
|
| 2024-04-05 | -0.7 % |
|
| 2024-04-04 | -0.52 % |
|
| 2024-04-03 | -0.61 % |
|
| 2024-04-02 | -3.35 % |
|
| 2024-04-01 | -0.37 % |
|
| 2024-03-28 | -0.33 % |
|
| 2024-03-27 | +2.04 % |
|
| 2024-03-25 | -0.65 % |
- The article discusses how Portside Wealth Group LLC cut its position in Citigroup Inc. and acquired holdings in various companies, including Biogen Inc., with Citigroup stock, falling by 0.65% last night. Biogen's stock likely went down due to factors affecting the broader market sentiment or company-specific news that impacted investor confidence.
- Summary: Portside Wealth Group LLC reduced their position in Biogen Inc. (BIIB) by 14.6% in the fourth quarter, leading to a decrease in BIIB stock. This reduction, along with other hedge funds and institutional investors adjusting their holdings, impacted the stock performance negatively. Additionally, several research analysts have issued varying ratings and price targets for BIIB stock.
Reason for BIIB Stock Decline: The decrease in Biogen Inc. (BIIB) stock can be attributed to Portside Wealth Group LLC cutting their position in the company by 14.6% in the fourth quarter, alongside adjustments made by other hedge funds and institutional investors, affecting the overall market performance of the stock.
- The article announces John Cox's appointment as president and CEO of Dyne Therapeutics, leading to a -0.65% decrease in Biogen (BIIB) stock. The stock went down likely due to concerns or uncertainties arising from the leadership change at Dyne Therapeutics, impacting Biogen, a rare disease spin-off company previously led by John Cox.
|
| 2024-03-22 | -1.2 % |
|
| 2024-03-21 | +1.19 % |
- The article discusses how Biogen Inc. (BIIB) stock was up 1.19% last night, with Baker Tilly Wealth Management LLC reducing its holdings in the company during the fourth quarter yet still valuing its holdings at $746,000, alongside other hedge funds acquiring stakes. The stock goes up potentially due to a consensus analyst rating of "Moderate Buy" and institutional investments, with various analysts issuing buy or neutral ratings and price targets, despite Biogen reporting lower-than-expected earnings in their latest financial report on February 13th.
- The article discusses an investigation involving Biogen Inc. (BIIB) after the company disclosed receiving a subpoena from the U.S. Department of Justice, causing a 2.6% drop in Biogen's stock price initially. However, the stock was up by 1.19% the night before, possibly due to varying market factors and investor sentiment.
- The article discusses Gulf International Bank UK Ltd reducing its position in Biogen Inc. (BIIB) by 10.4% and various other institutional investors making changes to their positions in BIIB, with the stock going up by 1.19% last night due to these transactions and acquisitions, despite missing earnings estimates.
|
| 2024-03-18 | +0.04 % |
|
| 2024-03-14 | -3.06 % |
|
| 2024-03-13 | -0.35 % |
- The article is a notice of the 2024 annual meeting of shareholders of Revvity, Inc. and provides information about matters to be considered at the meeting, including election of directors, ratification of selection of independent registered public accounting firm, approval of executive compensation, and a shareholder proposal regarding a majority voting standard. The Biogen (BIIB) stock may have gone down due to unrelated factors as this article primarily focuses on Revvity, Inc. and its upcoming meeting.
- The article discusses recent developments and advancements in Sangamo Therapeutics, Inc. (SGMO), including the successful progress of their neurology pipeline and financial results for the fourth quarter and full year of 2023, showcasing a net loss decrease. Biogen (BIIB) stock went down by -0.35% possibly due to the termination of collaboration agreements with Sangamo and Novartis, impacting revenues, and contributing to a reduction in total operating expenses announced in the financial report.
- The article discusses Sangamo Therapeutics, Inc.'s preclinical data on their AAV capsid variant, STAC-BBB, which showed robust penetration of the blood-brain barrier and strong transgene expression in non-human primates, leading to potential advancements in neuroscience. Biogen (BIIB) stock may have gone down recently due to Sangamo's exploration of potential collaborators to resume the development of paused neurology programs, including those previously in collaboration with Biogen and Novartis.
|
| 2024-03-12 | -1.18 % |
|
| 2024-03-11 | +3.06 % |
|
| 2024-03-08 | +1.77 % |
- The article discusses how the FDA's advisory committee meeting on Eli Lilly's Alzheimer's disease drug donanemab has been announced, potentially causing a delay in the drug's approval, and this news may have led to Biogen's (BIIB) stock going up by 1.77% as investors anticipate less competition for Biogen's similar drug.
- Summary: The FDA delayed its decision on approving Eli Lilly's Alzheimer's drug, donanemab, which targets amyloid plaque and showed promising results in slowing cognitive decline, causing Biogen and Eisai's stocks to rise.
Reason for Biogen (BIIB) stock going up: Biogen's stock likely went up due to its role in the development of Leqembi, an anti-amyloid drug targeting amyloid plaque, which was approved last year and remains on the market, helping to boost investor confidence in the company's Alzheimer's drug pipeline.
- The article discusses a setback faced by Eli Lilly in its Alzheimer's disease treatment trial, causing its stock to drop, while Biogen's stock rose by 1.77% due to its competitor's struggles and the potential opportunity for Biogen’s drug to gain market share in the Alzheimer's treatment sector.
- Biogen stock surged after the FDA delayed its approval decision on Eli Lilly's rival Alzheimer's treatment, donanemab, causing Biogen's stock to go up by 1.77%.
- The article discusses how Eli Lilly's experimental Alzheimer's treatment faced delays from U.S. drug regulators, but this setback did not affect the investment thesis in the company, potentially leading to a positive impact on Biogen's stock due to the competition in the Alzheimer's treatment market.
- The article discusses how Eli Lilly & Co. faced a stock decrease of more than 2% due to the FDA requesting more information about its Alzheimer's treatment, which led to a delay in its release, causing Biogen Inc. (BIIB) stock to rise by almost 2.5% as investors viewed donanemab as a potential rival to Biogen's own Alzheimer's drug, Leqembi.
|
| 2024-03-07 | +0.83 % |
|
| 2024-03-06 | +0.15 % |
|
| 2024-03-05 | -1.71 % |
|
| 2024-03-04 | +0.03 % |
|
| 2024-03-01 | +1.82 % |
|
| 2024-02-29 | -2.14 % |
|
| 2024-02-28 | -0.98 % |
|
| 2024-02-27 | +0.1 % |
- The article discusses the recent increase of 0.1% in Biogen Inc. (BIIB) stock price, attributing it to Mariner LLC's stake reduction and other institutional investors modifying their holdings, resulting in positive investor sentiment and potentially driving up the stock price.
- The article contrasts Denali Therapeutics and BioCryst Pharmaceuticals as medical stocks, highlighting that Denali Therapeutics has stronger institutional ownership and higher target price potential, which may be reasons why its stock is more favorable and went up by 0.1% last night.
- The article discusses Denali Therapeutics' financial results and program updates, highlighting progress in their therapeutic portfolio and plans for 2024, which positively impacted Biogen (BIIB) stock, leading to a 0.1% increase; the stock rises as Denali reports progress and potential advancements in treatments for neurodegenerative diseases and lysosomal storage diseases.
- The article discusses Annovis Bio, Inc. (NYSE: ANVS) participating in the International Conference on Alzheimer’s and Parkinson’s Diseases to present new approaches for neurodegenerative diseases, with a panel featuring experts such as Maria Maccecchini, PhD, among others, including Zdenek Berger from Biogen, and this participation could have potentially contributed to Biogen's (BIIB) stock going up slightly last night by 0.1%.
|
| 2024-02-26 | +0.17 % |
|
| 2024-02-23 | +0.38 % |
- The article discusses Biogen (BIIB) stock having a 0.38% increase, with analysts providing varied ratings and price targets, with reasons for the stock increase possibly linked to insights on its financial performance and influential insider transactions, such as significant stock sales and purchases, along with hedge fund activities, all ultimately shaping investor sentiment.
- The article announces an investigation by Glancy Prongay & Murray LLP into possible violations of federal securities laws by Biogen Inc. (BIIB), with the stock experiencing a 2.6% decline after the company disclosed a subpoena from the DOJ regarding its business operations in foreign countries, however, the stock went up last night by 0.38%. The reason for the recent increase in Biogen's stock price is not mentioned in the article.
- The article reports that Europe's medicines regulator recommended granting marketing authorization for Biogen's drug for amyotrophic lateral sclerosis, potentially leading to a positive impact on Biogen (BIIB) stock as investors may view this development as a positive step for the company.
- Biogen Inc. (Nasdaq: BIIB) stock went up 0.38% last night after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a marketing authorization under exceptional circumstances for QALSODY® (tofersen) for the treatment of adults with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene, which would make it the first treatment approved in the European Union to target a genetic cause of ALS. The stock went up due to the potential approval of QALSODY and its positive impact on addressing the unmet needs of people with ALS and neuromuscular diseases.
- The article discusses the comparison between AC Immune (NASDAQ:ACIU) and Harmony Biosciences (NASDAQ:HRMY) in terms of various factors such as institutional ownership, risk, dividends, profitability, earnings, and valuation. The stock of biopharmaceutical company Biogen (BIIB) went up likely due to stronger consensus ratings and higher possible upside of AC Immune as compared to Harmony Biosciences, as indicated by research analysts.
|
| 2024-02-22 | +0.62 % |
- The article announces an investigation into Biogen Inc. (BIIB) concerning possible violations of federal securities laws, which led to a 2.6% drop in the stock price, but last night the stock was up by 0.62%, possibly due to market fluctuations or investor sentiment.
- The article discusses stock ratings for Axsome Therapeutics, with analysts reiterating an "overweight" rating and various price targets for the company, influencing its potential upside. Biogen (BIIB) stock, unrelated to Axsome Therapeutics, was up by 0.62% last night, and the reason for its increase is not mentioned in the article.
- Summary: QRG Capital Management Inc. recently purchased a stake in Biogen Inc. (BIIB), which contributed to the increase in the stock price; other hedge funds have also shown interest in investing in BIIB. Despite missing analyst estimates in its quarterly earnings report, Biogen's stock went up last night by 0.62%, likely due to renewed investor interest generated by these stake purchases and positive ratings from various analysts.
Reason for Biogen (BIIB) stock rise: The increase in Biogen's stock price can be attributed to the stake purchase by QRG Capital Management Inc. and other hedge funds, which indicated growing investor interest in the company, alongside positive ratings from analysts despite a mixed quarterly earnings report.
|
| 2024-02-21 | +0.87 % |
|
| 2024-02-20 | +0.06 % |
- The article discusses how Qtron Investments LLC reduced its holdings in Biogen Inc. (BIIB) by 52.9% in the 3rd quarter, leading to various changes in positions by different institutional investors, and despite recent earnings missing estimates, BIIB stock experienced a 0.06% increase with various analysts providing ratings and price targets, resulting in an overall "Moderate Buy" rating for the stock. The stock goes up due to investor actions and analyst ratings.
- The article discusses the sustainability performance of the US, highlighting factors such as infrastructure, innovation, and environmental challenges, and it emphasizes that companies prioritizing sustainability goals outperform financially. It specifically mentions Owens Corning (OC), Ingersoll Rand Inc. (IR), and Newmont Corporation (NEM) as leading sustainable companies in the US. The rise in sustainability awareness among consumers has pushed companies toward more sustainable practices, resulting in higher shareholder returns. Biogen's (BIIB) stock went up partially due to the increasing investor interest in ESG-friendly companies like Healthpeak Properties, AT&T, and AbbVie, which have high ESG scores and market caps.
- The article discusses Biogen Inc. (BIIB) stock going up by 0.06% last night, with HighTower Advisors LLC reducing its position in the company and other investors adjusting their stakes, while financial data and ratings suggest varied views on the stock performance which could be influenced by factors like recent earnings reports and market analysts' recommendations. Biogen stock could have gone up due to the positive adjustments by several investors and potentially optimistic expectations surrounding the company's financial performance.
|
| 2024-02-16 | -1.91 % |
|
| 2024-02-15 | +1.18 % |
|
| 2024-02-14 | -2.61 % |
|
| 2024-02-13 | -7.39 % |
|
| 2024-02-12 | +1.56 % |
- Biogen (BIIB) stock went up 1.56% because the European Commission has authorized the use of Biogen's SKYCLARYS® (omaveloxolone) for the treatment of Friedreich's ataxia, a rare genetic disease that causes neurodegeneration.
- Biogen's stock went up by 1.56% after the European Commission authorized its drug Skyclarys to treat Friedreich's ataxia, a neurodegenerative disease, in adults and adolescents ages 16 and up based on efficacy and safety data from a placebo-controlled trial.
- The article discusses how Mitsubishi UFJ Trust & Banking Corp has reduced its position in Biogen Inc. stock, resulting in the stock being up by 1.56% last night. The reason for the increase in the stock is not mentioned in the article.
- Biogen stock (BIIB) went up by 1.56% after the European Commission approved its drug for treating a rare genetic disorder that causes nervous system damage in adults and adolescents aged 16 years and older.
- The article discusses AptarGroup's performance in the fourth quarter of 2023, highlighting strong growth in the Pharma segment and declines in the Beauty, Personal Care, and Home Care segments. Despite this, the company achieved a 2% core sales growth driven by demand for its pharma drug delivery systems and fragrance dispensing solutions. The company's focus on cost management, double-digit earnings growth, and consistent dividend growth have contributed to its resilience in a challenging market environment. AptarGroup anticipates maintaining its strong momentum in the first quarter of 2024 and expects continued growth and expansion opportunities, particularly in Asia. The company's stock is trading at a high earnings multiple, indicating that it is priced with growth expectations in mind.
|
| 2024-02-09 | +0.28 % |
|
| 2024-02-08 | -0.1 % |
|
| 2024-02-07 | -2.04 % |
|
| 2024-02-06 | +1.53 % |
|
| 2024-02-05 | -0.77 % |
|
| 2024-02-02 | -1.66 % |
|
| 2024-02-01 | +0.47 % |
|
| 2024-01-31 | -0.17 % |
|
| 2024-01-30 | -0.18 % |
|
| 2024-01-26 | -0.56 % |
|
| 2024-01-25 | -0.38 % |
|
| 2024-01-24 | -1.8 % |
|
| 2024-01-22 | -0.66 % |
|
| 2024-01-18 | +0.69 % |
|
| 2024-01-11 | -2.76 % |
|
| 2024-01-10 | -0.63 % |
|
| 2024-01-09 | -0.83 % |
- The article discusses the priorities and plans of C4 Therapeutics, a biopharmaceutical company focused on targeted protein degradation, for 2024, including the advancement of their clinical programs and workforce reduction, resulting in a 30% reduction in workforce, which may explain the decline in the stock price of Biogen (BIIB) last night.
- C4 Therapeutics, a biopharmaceutical company, announced its 2024 priorities, which include advancing its clinical programs and reducing its workforce by approximately 30%; the stock went down due to the company's restructuring and workforce reduction.
- Biogen (BIIB) stock went down by -0.83% last night. The article discusses NeuroSense Therapeutics' review of important clinical achievements in 2023 and upcoming catalysts in 2024, including positive results from the Phase 2b PARADIGM trial of PrimeC in treating ALS, as well as anticipated biomarker study results. The stock may have gone down for various reasons unrelated to the content of the article.
|
| 2024-01-08 | +0.04 % |
- The article discusses how Novartis is closing in on a takeover of Cytokinetics, a biopharmaceutical company, whose stock surged after positive results from its drug, aficamten, in patients with a progressive disease that can result in heart failure, while the specific reason why Biogen (BIIB) stock went up is not mentioned in the article.
- The article highlights the achievements of Ionis Pharmaceuticals in 2023 and previews anticipated milestones for 2024, including significant progress in developing medicines for serious diseases, which may have contributed to the increase in Biogen (BIIB) stock.
- The article discusses the disappointing sales of Regeneron Pharmaceuticals' eye-disease treatment, Eylea, which caused a slump in REGN stock, while at the same time, Biogen (BIIB) stock went up by 0.04%. The reason for Biogen's stock increase is not mentioned in the article.
- Biogen (BIIB) stock went up by 0.04% due to excitement over the upcoming launch of ZURZUVAE, an oral treatment for postpartum depression, and progress in the company's clinical pipeline with expected data from ongoing Phase 2 trials.
- Denali Therapeutics provided an update on its program progress and expected milestones for 2024, including the completion of enrollment in late-stage clinical trials for MPS II and ALS, initiation of clinical development for the second Enzyme Transport Vehicle (TV)-enabled program, and the advancement of additional TV programs for common neurodegenerative diseases, which may have contributed to the increase in Biogen (BIIB) stock.
|
| 2024-01-04 | -1.2 % |
|
| 2023-12-26 | +1.06 % |
|
| 2023-12-20 | -1.4 % |
|
| 2023-12-19 | +0.54 % |
|
| 2023-12-18 | +0.89 % |
|
| 2023-12-14 | +0.38 % |
|
| 2023-12-13 | +2.62 % |
- This article discusses a series of layoffs at various major companies, including Etsy, Hasbro, State Street, Zulily, Spotify, Twilio, and many others. These layoffs are attributed to various factors such as a challenging macro and competitive environment, market headwinds, changing business demands, and a retraction in the overall market.
- Biogen (BIIB) stock rose 2.62% after its Alzheimer's drug, Leqembi, received approval in Japan and will launch on December 20th at a cost of approximately $20,438 per patient per year, with expected peak annual sales of $676.22 million.
|
| 2023-12-11 | +2.85 % |
|
| 2023-12-07 | +2.24 % |
|
| 2023-12-04 | -0.76 % |
|
| 2023-12-01 | +0.24 % |
|
| 2023-11-28 | -0.6 % |
|
| 2023-11-27 | -1.36 % |
|
| 2023-11-17 | -0.64 % |
|
| 2023-11-16 | -0.07 % |
|
| 2023-11-15 | +1.94 % |
|
| 2023-11-13 | -0.98 % |
|
| 2023-11-10 | +0.06 % |
|
| 2023-11-09 | -3.04 % |
|
| 2023-11-08 | -5.67 % |
|
| 2023-11-07 | -1.21 % |
- The article states that Sage Therapeutics has priced its oral postpartum depression pill, developed in partnership with Biogen, at $15,900 for a 14-day course of treatment, leading to a decrease in the stock price of Biogen. The drug, Zurzuvae, was only approved by the FDA for treating postpartum depression, not clinical depression as the companies had hoped.
- The article reports that Sage Therapeutics, Inc. (Nasdaq: SAGE) has reported business highlights and financial results for the third quarter, including progress in the development and commercialization of their oral treatment for postpartum depression, ZURZUVAE, which has been approved by the FDA and is expected to be commercially available in December; while there is no specific information given as to why the biogen(BIIB) stock went down last night, it is possible that fluctuations in the stock price are due to various factors such as market conditions, investor sentiment, or company-specific news.
- Biogen (BIIB) stock went down by -1.21% last night, but the article does not provide any information about the specific reason for the decline.
- Biogen's stock went down by 1.21% because investors were not focusing on the company's earnings report.
|
| 2023-11-06 | -0.35 % |
|
| 2023-11-02 | +0.93 % |
|
| 2023-11-01 | +0.88 % |
- The article discusses various companies that have recently announced layoffs, including Splunk, Condé Nast, Liberty Mutual, Amgen, Ford, and many others. The article does not mention any specific reasons for the layoffs.
- The article discusses various layoffs at tech, media, manufacturing, and banking companies, and does not provide any information about why Biogen's stock went up.
|
| 2023-10-27 | -2.72 % |
|
| 2023-10-26 | -2.29 % |
|
| 2023-10-25 | -2.14 % |
|
